Agnes Medical Agnes RF
RF Microneedling · Precision single/tri-needle RF (eyes, acne)
What it's actually cleared for: Verified: K203013 cleared AGNES for dermatological and general surgical procedures for electrocoagulation and hemostasis — eye bags and acne-gland work are off-label uses of that clearance; more recent filings (K243713, K250217) exist and are worth reviewing for current labeling.
Last verified: August 6, 2026 · How we verify
New: $30k–$50k|Used: $15k–$25kmarket estimate, no email required
Bottom line
Not another all-purpose RF microneedling wand — a precision electrocoagulation tool built around partially insulated single and multi-needle tips that selectively destroy targets nothing else reaches non-surgically: under-eye fat pockets, sebaceous glands in recurring acne, syringomas, jowl fat. That focus is its moat and its ceiling: a specialist's device supporting premium niche pricing (eye bags at $2,000+ without a blepharoplasty) but not a general rejuvenation anchor. Verified FDA clearances and a growing US footprint make it more legitimate than its niche status suggests. Buy it as a differentiator, not a workhorse.
Overview
Niche precision device for eye bags/acne glands
How it works
The science
Focused RF through 9 specialized micro-insulated needle tips; insulation along the shaft confines thermal injury to the tip, allowing coagulation of a precise target — periorbital fat (eye bags), the sebaceous gland at the base of an acne pore, syringomas, small fat pads (jowls, double chin) — while sparing epidermis and surrounding dermis. For acne: destroying the gland aims at permanent elimination of the recurring lesion. For eye bags: coagulated fat is metabolized over 8-12 weeks with concurrent tightening. Local/topical anesthesia, a few days of swelling.
Patented tech
The micro-insulated needle system itself — variable insulation lengths and gauges per tip matched to target depth, plus impedance-controlled RF dosing; a very refined electrocoagulation needle set rather than a novel energy source.
Origin
South Korea (Agnes Medical Co., Ltd.); US distribution via Agnes America / Aesthetic Management Partners.
FDA & regulatory status
What it's actually cleared for:
Verified: K203013 cleared AGNES for dermatological and general surgical procedures for electrocoagulation and hemostasis — eye bags and acne-gland work are off-label uses of that clearance; more recent filings (K243713, K250217) exist and are worth reviewing for current labeling.
Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.
Treatment economics
What practices charge
Eye-bag treatment $1,500-3,500 per session, most patients 1-2 sessions — positioned against $4,000-7,000 lower-bleph surgery. Acne (gland ablation) $500-1,200 per session over 2-3; jowl/submental contouring $1,200-2,500.
Consumables & recurring cost
Single-use needle tips; modest per-case cost (generally under ~$100 each — verify with AMP); niche volume keeps annual spend low five figures or less.
Ideal for
Best-fit practice
Derm, oculoplastic, and cosmetic-surgery-adjacent practices that can clinically own periorbital work, or medspas with strong acne clientele wanting a "we can actually stop the recurring cyst" offer. Patients: 30s-60s eye-bag candidates avoiding surgery; 20s-40s stubborn-acne patients who've cycled through everything.
Compliance
Medical director & delegation
Class II electrosurgical device; periorbital fat coagulation is closer to a medical procedure than a facial — most practices keep it physician- or NP/PA-performed rather than delegating.
Contraindications & screening
Pacemakers/implanted electronics, pregnancy, active infection, keloid propensity, anticoagulation issues for periorbital work, severe skin-excess cases that truly need surgery.
Ownership
Warranty & service
~1-year warranty through the US distributor with extended options — verify terms with Aesthetic Management Partners including loaner availability; service depth is distributor-dependent.
Resale & used market
Thin, specialist-driven used market — infrequent listings, narrow buyer pool, slower liquidation but reasonable price retention given low unit volume.
Chains using this device
No confirmed chain deployments recorded yet.
Owner reviews
Write a reviewNo approved reviews yet. Be the first owner to publish one.
Alternatives
History
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Get the full State of Aesthetic Devices 2026 report
The first independent census of the US aesthetic device market — free.